Medtronic Bets $80 Million on Pi-Cardia to Advance TAVR Procedures

The agreement grants Medtronic exclusive global distribution rights for the ShortCut device starting in 2027, leveraging its extensive commercial network across the United States, Europe, and Japan. Beyond the initial capital infusion, the contract includes a predefined pathway for a potential acquisition of Pi-Cardia, valued at up to $210 million plus additional performance-based earn-outs, pending regulatory approvals.

For Medtronic, the partnership bridges a critical gap in transcatheter aortic valve replacement (TAVR). As patient demographics skew toward more complex anatomical profiles, the ability to preserve coronary access becomes a standard necessity rather than an edge case. Pi-Cardia’s platform, which demonstrated consistent success in pivotal FDA-reviewed clinical trials, provides a reproducible method for leaflet splitting that the company aims to integrate into routine clinical practice. Erez Golan, CEO of Pi-Cardia, noted that aligning with a global leader provides the necessary infrastructure to scale this technology, effectively turning a specialized tool into a fundamental component of structural heart interventions.